规格:100ul
研究领域:细胞生物 神经生物学 信号转导 细胞凋亡 Alzheimer's
抗体来源:Mouse
克隆类型:Polyclonal
交叉反应:Rat,
(predicted: Human, Mouse, Chicken, Dog, Pig, Cow, Rabbit, )
产品应用:ICC=1:50-200 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量:4.4kDa
性 状:Lyophilized or Liquid
浓 度:1mg/ml
免 疫 原:KLH conjugated synthetic peptide derived from human beta-Amyloid
亚 型:IgG
纯化方法:affinity purified by Protein A
储 存 液:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件:Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍:background:The cerebral and vascular plaques associated with Alzheimer's disease are mainly composed of Amyloid beta peptides. beta Amyloid is derived from cleavage of the Amyloid precursor protein and varies in length from 39 to 43 amino acids. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides result from cleavage of Amyloid precursor protein after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last Amyloid precursor protein processing step. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides are major constituents of the plaques and tangles that occur in Alzheimer's disease. beta Amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimer's disease.
Function:Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons.
Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity.
Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brai.
The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).
Subunit:Binds, via its C-terminus, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, MAPK8IP1, SHC1 and, NUMB and DAB. Binding to DAB1 inhibits its serine phosphorylation (By similarity). Also interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains), APPBP2 (via BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains. Associates with microtubules in the presence of ATP and in a kinesin-dependent manner. Interacts, through a C-terminal domain, with GNAO1. Amyloid beta-42 binds CHRNA7 in hippocampal neurons. Beta-amyloid associates with HADH2. Soluble APP binds, via its N-terminal head, to FBLN1. Interacts with CPEB1 and AGER. Interacts with ANKS1B and TNFRSF21. Interacts with ITM2B. Interacts with ITM2C. Interacts with IDE. Can form homodimers; this is promoted by heparin binding.
Subcellular Location:Membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit. Note=Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with APBB1 (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment.
Tissue Specificity:Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex-opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra-striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes.
Post-translational modifications:Proteolytically processed under normal cellular conditions. Cleavage either by alpha-secretase, beta-secretase or theta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).
Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides.
N- and O-glycosylated. O-linkage of chondroitin sulfate to the L-APP isoforms produces the APP proteoglycan core proteins, the appicans. The chondroitin sulfate chain of appicans contains 4-O-sulfated galactose in the linkage region and chondroitin sulfate E in the repeated disaccharide region.
Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin.
Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides.
Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP).
Beta-amyloid peptides are degraded by IDE.
DISEASE:Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:104300]. AD1 is a familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.
Defects in APP are the cause of amyloidosis cerebroarterial Dutch type (AMYLCAD) [MIM:605714]; also known as hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWAD). AMYLCAD is a hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels. Beta-APP40 is the predominant form of cerebrovascular amyloid. Amyloid is not found outside the nervous system. The principal clinical characteristics are recurrent cerebral and cerebellar hemorrhages, recurrent strokes, cerebral ischemia, cerebral infarction, and progressive mental deterioration. Onset of the disease is in middle age (44 to 60 years). Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare and largely in the form of pre-amyloid lesions or diffuse plaque-like structures. They are Congo red negative and lack the dense amyloid cores commonly present in Alzheimer disease.
Defects in APP are the cause of amyloidosis cerebroarterial Italian type (AMYLCAIT) [MIM:605714]. AMYLCAIT is a hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels, resulting in cerebral amyloid angiopathy. Amyloid is not found outside the nervous system. It is a condition very similar to AMYLCAD, but the clinical course is less severe. Patients manifest mild cognitive decline, recurrent strokes, and epilepsy in some cases. There are extensive amyloid deposits in leptomeningeal and cortical vessels and, to a lesser extent, in the neuropil of the cerebral cortex, in the absence of neurofibrillary tangles.
Defects in APP are the cause of amyloidosis cerebroarterial Iowa type (AMYLCAIW) [MIM:605714]. AMYLCAIW is a hereditary amyloidosis due to amyloid-beta A4 peptide(s) deposition. Patients have progressive aphasic dementia, leukoencephalopathy, and occipital calcifications.
Similarity:Belongs to the APP family. Contains 1 BPTI/Kunitz inhibitor domain.
Database links:
Entrez Gene: 351 Human
Entrez Gene: 11820 Mouse
Entrez Gene: 54226 Rat
Omim: 104760 Human
SwissProt: P05067 Human
SwissProt: P12023 Mouse
SwissProt: P08592 Rat
Unigene: 434980 Human
Unigene: 277585 Mouse
Unigene: 2104 Rat
Important Note:This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
111β-Amyloid 也称β-A4 蛋白、Aβ1-42，是β-淀粉样蛋白前体（APP）经β和γ分泌酶分解后的产物，有39-43个氨基酸残基组成。是淀粉样蛋白的主要成分。此蛋白在大脑中形成不容性的沉积物(老年斑),从而具有特殊的AD,Down's综合症和老年痴呆症的形态学特征。β-淀粉样蛋白来自β-淀粉样蛋白原，在脑组织的细胞外呈丝状蛋白样沉积，是淀粉样结节性神经炎病变的主要蛋白成分，在神经纤维中也有沉积。
在老年性痴呆Alzheimer病中，大脑皮质中特征性地出现β-淀粉样蛋白沉积形成的老年斑。主要用于老年性痴呆症病人大脑组织噬斑中淀粉样物质的检测。必要时石蜡组织切片用98-100%甲酸处理2-3分钟。
222
研究领域:细胞生物 神经生物学 信号转导 细胞凋亡 Alzheimer's
抗体来源:Mouse
克隆类型:Polyclonal
交叉反应:Rat,
(predicted: Human, Mouse, Chicken, Dog, Pig, Cow, Rabbit, )
产品应用:ICC=1:50-200 IF=1:50-200
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量:4.4kDa
性 状:Lyophilized or Liquid
浓 度:1mg/ml
免 疫 原:KLH conjugated synthetic peptide derived from human beta-Amyloid
亚 型:IgG
纯化方法:affinity purified by Protein A
储 存 液:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件:Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍:background:The cerebral and vascular plaques associated with Alzheimer's disease are mainly composed of Amyloid beta peptides. beta Amyloid is derived from cleavage of the Amyloid precursor protein and varies in length from 39 to 43 amino acids. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides result from cleavage of Amyloid precursor protein after residues 40, 42, and 43, respectively. The cleavage takes place by gamma-secretase during the last Amyloid precursor protein processing step. beta Amyloid [1-40], beta Amyloid [1-42], and beta Amyloid [1-43] peptides are major constituents of the plaques and tangles that occur in Alzheimer's disease. beta Amyloid antibodies and peptides have been developed as tools for elucidating the biology of Alzheimer's disease.
Function:Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity. Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons.
Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Beta-amyloid 42 is a more effective reductant than beta-amyloid 40. Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity.
Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brai.
The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).
Subunit:Binds, via its C-terminus, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, MAPK8IP1, SHC1 and, NUMB and DAB. Binding to DAB1 inhibits its serine phosphorylation (By similarity). Also interacts with GPCR-like protein BPP, FPRL1, APPBP1, IB1, KNS2 (via its TPR domains), APPBP2 (via BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains. Associates with microtubules in the presence of ATP and in a kinesin-dependent manner. Interacts, through a C-terminal domain, with GNAO1. Amyloid beta-42 binds CHRNA7 in hippocampal neurons. Beta-amyloid associates with HADH2. Soluble APP binds, via its N-terminal head, to FBLN1. Interacts with CPEB1 and AGER. Interacts with ANKS1B and TNFRSF21. Interacts with ITM2B. Interacts with ITM2C. Interacts with IDE. Can form homodimers; this is promoted by heparin binding.
Subcellular Location:Membrane; Single-pass type I membrane protein. Membrane, clathrin-coated pit. Note=Cell surface protein that rapidly becomes internalized via clathrin-coated pits. During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. Gamma-CTF(59) peptide is located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with APBB1 (Fe65). Beta-APP42 associates with FRPL1 at the cell surface and the complex is then rapidly internalized. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body. Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment.
Tissue Specificity:Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex-opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra-striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes.
Post-translational modifications:Proteolytically processed under normal cellular conditions. Cleavage either by alpha-secretase, beta-secretase or theta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).
Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides.
N- and O-glycosylated. O-linkage of chondroitin sulfate to the L-APP isoforms produces the APP proteoglycan core proteins, the appicans. The chondroitin sulfate chain of appicans contains 4-O-sulfated galactose in the linkage region and chondroitin sulfate E in the repeated disaccharide region.
Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific. Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins. Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta. The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members. Phosphorylation on Tyr-757 is required for SHC binding. Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin.
Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of beta-amyloid-containing peptides.
Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP).
Beta-amyloid peptides are degraded by IDE.
DISEASE:Defects in APP are the cause of Alzheimer disease type 1 (AD1) [MIM:104300]. AD1 is a familial early-onset form of Alzheimer disease. It can be associated with cerebral amyloid angiopathy. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death.
Defects in APP are the cause of amyloidosis cerebroarterial Dutch type (AMYLCAD) [MIM:605714]; also known as hereditary cerebral hemorrhage with amyloidosis Dutch type (HCHWAD). AMYLCAD is a hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels. Beta-APP40 is the predominant form of cerebrovascular amyloid. Amyloid is not found outside the nervous system. The principal clinical characteristics are recurrent cerebral and cerebellar hemorrhages, recurrent strokes, cerebral ischemia, cerebral infarction, and progressive mental deterioration. Onset of the disease is in middle age (44 to 60 years). Patients develop cerebral hemorrhage because of the severe cerebral amyloid angiopathy. Parenchymal amyloid deposits are rare and largely in the form of pre-amyloid lesions or diffuse plaque-like structures. They are Congo red negative and lack the dense amyloid cores commonly present in Alzheimer disease.
Defects in APP are the cause of amyloidosis cerebroarterial Italian type (AMYLCAIT) [MIM:605714]. AMYLCAIT is a hereditary localized amyloidosis due to amyloid-beta A4 peptide(s) deposition in the cerebral vessels, resulting in cerebral amyloid angiopathy. Amyloid is not found outside the nervous system. It is a condition very similar to AMYLCAD, but the clinical course is less severe. Patients manifest mild cognitive decline, recurrent strokes, and epilepsy in some cases. There are extensive amyloid deposits in leptomeningeal and cortical vessels and, to a lesser extent, in the neuropil of the cerebral cortex, in the absence of neurofibrillary tangles.
Defects in APP are the cause of amyloidosis cerebroarterial Iowa type (AMYLCAIW) [MIM:605714]. AMYLCAIW is a hereditary amyloidosis due to amyloid-beta A4 peptide(s) deposition. Patients have progressive aphasic dementia, leukoencephalopathy, and occipital calcifications.
Similarity:Belongs to the APP family. Contains 1 BPTI/Kunitz inhibitor domain.
Database links:
Entrez Gene: 351 Human
Entrez Gene: 11820 Mouse
Entrez Gene: 54226 Rat
Omim: 104760 Human
SwissProt: P05067 Human
SwissProt: P12023 Mouse
SwissProt: P08592 Rat
Unigene: 434980 Human
Unigene: 277585 Mouse
Unigene: 2104 Rat
Important Note:This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
111β-Amyloid 也称β-A4 蛋白、Aβ1-42，是β-淀粉样蛋白前体（APP）经β和γ分泌酶分解后的产物，有39-43个氨基酸残基组成。是淀粉样蛋白的主要成分。此蛋白在大脑中形成不容性的沉积物(老年斑),从而具有特殊的AD,Down's综合症和老年痴呆症的形态学特征。β-淀粉样蛋白来自β-淀粉样蛋白原，在脑组织的细胞外呈丝状蛋白样沉积，是淀粉样结节性神经炎病变的主要蛋白成分，在神经纤维中也有沉积。
在老年性痴呆Alzheimer病中，大脑皮质中特征性地出现β-淀粉样蛋白沉积形成的老年斑。主要用于老年性痴呆症病人大脑组织噬斑中淀粉样物质的检测。必要时石蜡组织切片用98-100%甲酸处理2-3分钟。
222
COA搜索：
免责申明：
本网站所提供的信息，只供参考之用。
本网站及其雇员一概毋须以任何方式就任何信息传递或传送的失误、不准确或错误对用户或任何其他人士负任何直接或间接的责任。
在法律允许的范围内，本网站在此声明,不承担用户或任何人士就使用或未能使用本网站所提供的信息或任何链接或项目所引致的任何直接、间接、附带、从属、特殊、惩罚性或惩戒性的损害赔偿（包括但不限于收益、预期利润的损失或失去的业务、未实现预期的节省）。
本网站所提供的信息，若在任何司法管辖地区供任何人士使用或分发给任何人士时会违反该司法管辖地区的法律或条例的规定或会导致本网站或其第三方代理人受限于该司法管辖地区内的任何监管规定时，则该等信息不宜在该司法管辖地区供该等任何人士使用或分发给该等任何人士。用户须自行保证不会受限于任何限制或禁止用户使用或分发本网站所提供信息的当地的规定。
本网站图片，文字之类版权申明，因为网站可以由注册用户自行上传图片或文字，本网站无法鉴别所上传图片或文字的知识版权，如果侵犯，请及时通知我们，本网站将在第一时间及时删除。
凡以任何方式登录本网站或直接、间接使用本网站资料者，视为自愿接受本网站声明的约束。
通用销售条款
一． 买方对产品的使用：产品应当用于实验室研究目的，不可用作其他用途（包括但不限于：体外诊断、食品、药物、医疗器械、人用或兽用治疗、化妆品或其他商业用途）。购买方应明确清楚知道此声明，并严格遵守。如有任何因购买方隐瞒真实购买意图，由此引起的法律责任以及一切法律后果，由购买方承担。
二． 准确订货：下订单时，买方应预先仔细审阅产品的技术指标，确认无误。不详之处应立即查询。订单及产品一经发出，即视为买方认可有关产品的技术指标。
三． 质量责任：我司保证所供产品质量与随货COA所列标准相符。买方应以产品制造商的标准作为验收标准。鉴于化学品的特殊性，卖方对未使用之前的产品质量负责，对化学品的应用不负有任何直接与间接的责任。卖方提醒买方：在做实验之前，预先按照技术规范检验产品质量。在产品开始使用之后，买方对应用及其结果负有全部责任。若有质量异议，买方需在收到货物后10个工作日内书面通知卖方，过期无效。
四． 有限保证：在适用法律允许的最大限度内，卖方提供的产品均“按现状条件”提供给买方，卖方不作对产品和/或其使用的各种明示或默示的保证（包括但不限于对适销性、适合用于特殊用途及不侵权的所有明示或默示保证）或卖方产品会达到任何特定结果或不会被中断或不会有错误的保证。
五． 责任限制：在适用法律允许的最大限度内，卖方不对以任何方式由本合同、卖方产品或使用卖方产品引起的或与此有关的任何利润或收入损失或其他后果性损失、随附性损失、特殊损失、惩罚性损失或任何其他间接损失或损害承担责任。在适用法律允许的最大限度内，卖方的最高赔偿限额为买方就所涉及的卖方产品实际支付给卖方的价格。
六． 如卖方因不可抗拒力原因无法供货，卖方将及时通知买方，双方将视情况决定部分不履行、全部不履行或延期履行；如供货期限届满日为国内外重大节日或国家法定假日，则供货期限顺延；若因缺货导致延期交货或无法供货，卖方将及时告知买方，并不视为卖方违约。不可抗力：因火灾、洪水、风暴、爆炸、恐怖事件、战争、政府行为或任何其他卖方无法预见、无法避免和无法克服的事件造成延期交货或无法交货的，卖方不承担任何责任。
订购方式：
（1）直接注册www.ruichubio.com网站会员后直接在线订购支持支付宝、微信和公务卡支付；
（2）拨打021-59145618订购热线订购;
（3）登录www.ruichubio.com下载中心下载订购单发送至：order@ruichubio.com订购
注：在邮件确认合同或订购单情况下，可以货物和发票一起寄送，对公转账。
发票：
本公司出具增值税普通发票和增值税专用发票，适合您报销。发票面额为含税后的货物价格和运费，请您放心购买，我们会将运费开进发票里。请在拍下时在备注一栏里写上发票抬头。
支付：
开票账户：
公司名称 上海瑞楚生物科技有限公司
电话 021-60543596
纳税人识别号 91310116057685530X
开户银行全称 中国银行股份有限公司上海市长宁支行
帐号 454663168779
支付宝转账请支付到如下账户
帐 户 名 上海瑞楚生物科技有限公司
账 号 epay@ruichubio.com
为了方便高校科研单位公务卡结算，本网站开通了公务卡支付。可以在线下单选择支付宝付款，登录支付宝账号添加银行卡（输入公务卡号就可以）（公务卡一般就是信用卡,请按信用卡支付方式支付)。
运输：
（1）生物试剂需要冷冻运输，运输需要泡沫盒和一定量的冰袋（特殊商品需要干冰），运费金额会开进发票里。运费以显示为准
（2）常规试剂采用快递，运费以显示为准。
（3）大物件一般默认发德邦物流，运费需联系客服计算。
本网站所提供的信息，只供参考之用。
本网站及其雇员一概毋须以任何方式就任何信息传递或传送的失误、不准确或错误对用户或任何其他人士负任何直接或间接的责任。
在法律允许的范围内，本网站在此声明,不承担用户或任何人士就使用或未能使用本网站所提供的信息或任何链接或项目所引致的任何直接、间接、附带、从属、特殊、惩罚性或惩戒性的损害赔偿（包括但不限于收益、预期利润的损失或失去的业务、未实现预期的节省）。
本网站所提供的信息，若在任何司法管辖地区供任何人士使用或分发给任何人士时会违反该司法管辖地区的法律或条例的规定或会导致本网站或其第三方代理人受限于该司法管辖地区内的任何监管规定时，则该等信息不宜在该司法管辖地区供该等任何人士使用或分发给该等任何人士。用户须自行保证不会受限于任何限制或禁止用户使用或分发本网站所提供信息的当地的规定。
本网站图片，文字之类版权申明，因为网站可以由注册用户自行上传图片或文字，本网站无法鉴别所上传图片或文字的知识版权，如果侵犯，请及时通知我们，本网站将在第一时间及时删除。
凡以任何方式登录本网站或直接、间接使用本网站资料者，视为自愿接受本网站声明的约束。
通用销售条款
一． 买方对产品的使用：产品应当用于实验室研究目的，不可用作其他用途（包括但不限于：体外诊断、食品、药物、医疗器械、人用或兽用治疗、化妆品或其他商业用途）。购买方应明确清楚知道此声明，并严格遵守。如有任何因购买方隐瞒真实购买意图，由此引起的法律责任以及一切法律后果，由购买方承担。
二． 准确订货：下订单时，买方应预先仔细审阅产品的技术指标，确认无误。不详之处应立即查询。订单及产品一经发出，即视为买方认可有关产品的技术指标。
三． 质量责任：我司保证所供产品质量与随货COA所列标准相符。买方应以产品制造商的标准作为验收标准。鉴于化学品的特殊性，卖方对未使用之前的产品质量负责，对化学品的应用不负有任何直接与间接的责任。卖方提醒买方：在做实验之前，预先按照技术规范检验产品质量。在产品开始使用之后，买方对应用及其结果负有全部责任。若有质量异议，买方需在收到货物后10个工作日内书面通知卖方，过期无效。
四． 有限保证：在适用法律允许的最大限度内，卖方提供的产品均“按现状条件”提供给买方，卖方不作对产品和/或其使用的各种明示或默示的保证（包括但不限于对适销性、适合用于特殊用途及不侵权的所有明示或默示保证）或卖方产品会达到任何特定结果或不会被中断或不会有错误的保证。
五． 责任限制：在适用法律允许的最大限度内，卖方不对以任何方式由本合同、卖方产品或使用卖方产品引起的或与此有关的任何利润或收入损失或其他后果性损失、随附性损失、特殊损失、惩罚性损失或任何其他间接损失或损害承担责任。在适用法律允许的最大限度内，卖方的最高赔偿限额为买方就所涉及的卖方产品实际支付给卖方的价格。
六． 如卖方因不可抗拒力原因无法供货，卖方将及时通知买方，双方将视情况决定部分不履行、全部不履行或延期履行；如供货期限届满日为国内外重大节日或国家法定假日，则供货期限顺延；若因缺货导致延期交货或无法供货，卖方将及时告知买方，并不视为卖方违约。不可抗力：因火灾、洪水、风暴、爆炸、恐怖事件、战争、政府行为或任何其他卖方无法预见、无法避免和无法克服的事件造成延期交货或无法交货的，卖方不承担任何责任。
订购方式：
（1）直接注册www.ruichubio.com网站会员后直接在线订购支持支付宝、微信和公务卡支付；
（2）拨打021-59145618订购热线订购;
（3）登录www.ruichubio.com下载中心下载订购单发送至：order@ruichubio.com订购
注：在邮件确认合同或订购单情况下，可以货物和发票一起寄送，对公转账。
发票：
本公司出具增值税普通发票和增值税专用发票，适合您报销。发票面额为含税后的货物价格和运费，请您放心购买，我们会将运费开进发票里。请在拍下时在备注一栏里写上发票抬头。
支付：
开票账户：
公司名称 上海瑞楚生物科技有限公司
电话 021-60543596
纳税人识别号 91310116057685530X
开户银行全称 中国银行股份有限公司上海市长宁支行
帐号 454663168779
帐 户 名 上海瑞楚生物科技有限公司
账 号 epay@ruichubio.com
为了方便高校科研单位公务卡结算，本网站开通了公务卡支付。可以在线下单选择支付宝付款，登录支付宝账号添加银行卡（输入公务卡号就可以）（公务卡一般就是信用卡,请按信用卡支付方式支付)。
运输：
（1）生物试剂需要冷冻运输，运输需要泡沫盒和一定量的冰袋（特殊商品需要干冰），运费金额会开进发票里。运费以显示为准
（2）常规试剂采用快递，运费以显示为准。
（3）大物件一般默认发德邦物流，运费需联系客服计算。
